We are live on ! Find out more
CRBU icon

Caribou Biosciences

140 hedge funds and large institutions have $87.6M invested in Caribou Biosciences in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 41 increasing their positions, 43 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% less repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 43

7% less funds holding

Funds holding: 151140 (-11)

15.05% less ownership

Funds ownership: 73.91%58.86% (-15%)

25% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 36

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

67% less call options, than puts

Call options by funds: $54K | Put options by funds: $163K

74% less capital invested

Capital invested by funds: $343M → $87.6M (-$255M)

Holders
140
Holders Change
-11
Holders Change %
-7.28%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
27
Increased
41
Reduced
43
Closed
36
Calls
$54K
Puts
$163K
Net Calls
-$109K
Net Calls Change
-$182K
Name Holding Trade Value Shares
Change
Change in
Stake
TWM
76
Thrive Wealth Management
Pennsylvania
$52.5K
PAS
77
Point72 Asia (Singapore)
Singapore
$52.2K +$102K +31,831 New
PD
78
Point72 (DIFC)
United Arab Emirates
$49.5K +$76.7K +23,995 +389%
Walleye Trading
79
Walleye Trading
New York
$49.2K -$227 -71 -0.2%
AA
80
Ancora Advisors
Ohio
$49.2K +$32K +10,000 +50%
Deutsche Bank
81
Deutsche Bank
Germany
$49.2K -$18.2K -5,693 -16%
SAM
82
Stansberry Asset Management
Texas
$49.1K -$110K -34,368 -53%
VOYA Investment Management
83
VOYA Investment Management
Georgia
$45.6K +$2.4K +751 +3%
PCM
84
Prelude Capital Management
New York
$43.3K +$21.7K +6,800 +35%
FIM
85
Freedom Investment Management
Connecticut
$42.3K +$82.5K +25,807 New
AIM
86
Aigen Investment Management
New York
$40.1K +$78.1K +24,428 New
T. Rowe Price Associates
87
T. Rowe Price Associates
Maryland
$40K +$1.83K +572 +2%
SG Americas Securities
88
SG Americas Securities
New York
$38K -$10.3K -3,224 -12%
YIH
89
Y-Intercept (HK)
Hong Kong
$36.1K +$37.1K +11,604 +112%
State Board of Administration of Florida Retirement System
90
State Board of Administration of Florida Retirement System
Florida
$35K +$68.1K +21,320 New
Verition Fund Management
91
Verition Fund Management
Connecticut
$32.1K +$62.5K +19,562 New
AQR Capital Management
92
AQR Capital Management
Connecticut
$30.1K +$58.6K +18,341 New
SFI
93
Susquehanna Fundamental Investments
Pennsylvania
$27.8K -$293K -91,637 -84%
ProShare Advisors
94
ProShare Advisors
Maryland
$27.1K -$14K -4,366 -21%
PCIA
95
Prime Capital Investment Advisors
Kansas
$26.3K -$933 -292 -2%
LP
96
LMR Partners
United Kingdom
$24.9K
EAM
97
Erste Asset Management
Austria
$23.4K
Cetera Investment Advisers
98
Cetera Investment Advisers
Illinois
$21.2K +$41.4K +12,943 New
PA
99
Pinnacle Associates
New York
$21.2K
PWMAG
100
Pinnacle Wealth Management Advisory Group
New Jersey
$21.2K

CRBU Hedge Fund Activity: Q2 2024 in Review

140 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q2 2024, worth a combined $87.6M — down 74% from $343M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CRBU and 27 opened new positions — a net loss of 9 holders — while 43 trimmed existing stakes and 41 added.

The largest buyer was Bank of America, adding an estimated $9.73M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $29.7M sold.

  • 140 institutional investors held Caribou Biosciences (CRBU) as of Q2 2024, down from 151 in Q1 2024.
  • Funds reported $87.6M of Caribou Biosciences stock for Q2 2024, down 74% quarter-over-quarter.
  • 27 funds opened new Caribou Biosciences positions in Q2 2024 and 36 closed out, a net change of -9 holders.
  • The largest Caribou Biosciences buyer in Q2 2024 was Bank of America, an estimated $9.73M added.
  • The largest Caribou Biosciences seller in Q2 2024 was Avidity Partners Management, an estimated $29.7M sold.

Based on aggregated 13F filings for Q2 2024.